BioPharma Resources

Drug Trial Radar · NCT06537414

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 283 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

283

Actual

Start

Nov 11, 2024

Primary completion

May 31, 2027

Study completion May 17, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen. The study will also include an optional long-term follow-up (LTFU) extension stage for eligible participants.

Conditions

  • Chronic Hepatitis B Virus Infection
  • Hepatitis B

Interventions

  • Daplusiran/Tomligisiran Dose Level 1Drug

    Daplusiran/Tomligisiran dose level 1 will be administered

  • Daplusiran/Tomligisiran Dose Level 2Drug

    Daplusiran/Tomligisiran dose level 2 will be administered

  • BepirovirsenDrug

    Bepirovirsen will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants achieving functional cureTime frame: Up to 100 Weeks

Locations

80 sites in 19 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Westmead, New South Wales, Australia

  • GSK Investigational Site

    Fitzroy, Victoria, Australia

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Edegem, Belgium

  • GSK Investigational Site

    Ghent, Oost-Vlaanderen, Belgium

  • GSK Investigational Site

    Aracaju, Brazil

  • GSK Investigational Site

    Curitiba, Brazil

  • GSK Investigational Site

    Manaus, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Chengdu, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Clichy, France

  • GSK Investigational Site

    Créteil, France

  • GSK Investigational Site

    Limoges, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Münster, Germany

  • GSK Investigational Site

    Hanover, Lower Saxony, Germany

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Pokfulam, Hong Kong

  • GSK Investigational Site

    Shatin, Hong Kong

  • GSK Investigational Site

    Bergamo, Italy

  • GSK Investigational Site

    Florence, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Naples, Italy

  • GSK Investigational Site

    Padova, Italy

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.